BioRestorative Therapies, Inc.

BRTX

US0906556065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/06/2025 BST			5-day change	1st Jan Change
1.680 ^USD	-16.00%		-6.93%	+17.48%

06-13	BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease	CI
06-13	BioRestorative Therapies Says BRTX-100 Improved Function in Phase 2 Chronic Lumbar Disc Disease Trial	MT

Top Premarket Decliners

Published on 06/02/2024 at 12:44, updated on 06/02/2024 at 13:03

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about BioRestorative Therapies, Inc.

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 - an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease	06-13	CI
BioRestorative Therapies Says BRTX-100 Improved Function in Phase 2 Chronic Lumbar Disc Disease Trial	06-13	MT
BioRestorative Reports Compelling Preliminary Data For FDA-Fast-Tracked BRTX-100	06-13	RE
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025	06-09	CI
BioRestorative Therapies, Inc., Q1 2025 Earnings Call, May 14, 2025	05-27
BioRestorative Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-14	CI
BioRestorative Therapies, Inc. Announces Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data	05-13	CI
BioRestorative Therapies, Inc. to Present a BRTX-100 Clinical Update at ISCT 2025	05-07	CI
BioRestorative confirms no material impact from reciprocal tariffs	04-10	RE
BioRestorative Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	03-28	CI
BioRestorative Therapies, Inc. Auditor Raises 'Going Concern' Doubt	03-27	CI
BioRestorative Therapies, Inc., 2024 Earnings Call, Mar 27, 2025	03-27
BioRestorative Therapies Says FDA Clears BRTX-100 Trial in Chronic Cervical Discogenic Pain	02-27	MT
BioRestorative Therapies, Inc. - Special Call	02-27
BioRestorative Therapies, Inc. Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain	02-27	CI
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program	02-20	CI
BioRestorative Therapies, Inc. Presents 26-52 Week Blinded Data from the First 15 Patients (Up from 10 Reported Previously with Chronic Lumbar Disc Disease (?cLDD?) Enrolled in the Ongoing Phase 2 Clinical Trial of BRTX-100 At the Orthopaedic Research Society	02-10	CI
BioRestorative Therapies, Inc., Q3 2024 Earnings Call, Nov 13, 2024	11-13
BioRestorative Therapies, Inc. Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data	11-13	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-12	CI
BioRestorative Therapies, Inc. Receives Expanded Tissue License from New York State Department of Health	11-05	CI
BioRestorative Therapies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	13/08/24	CI
BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program	27/06/24	CI
Top Midday Gainers	13/06/24	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	13/06/24	MT

Chart BioRestorative Therapies, Inc.

Duration

Period

BRTX: Dynamic Chart

BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-18 - Q2 2025 Earnings Release (Projected)

More about the company